Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States of America.
Bull World Health Organ. 2010 Feb;88(2):104-12. doi: 10.2471/BLT.08.058230. Epub 2010 Jan 8.
To evaluate the cost-effectiveness of topical emollients, sunflower seed oil (SSO) and synthetic Aquaphor, versus no treatment, in preventing mortality among hospitalized preterm infants (< 33 weeks gestation) at a tertiary hospital in Bangladesh.
Evidence from a randomized controlled efficacy trial was evaluated using standard Monte Carlo simulation. Programme costs were obtained from a retrospective review of activities. Patient costs were collected from patient records. Health outcomes were calculated as deaths averted and discounted years of life lost (YLLs) averted. Results were deemed cost-effective if they fell below a ceiling ratio based on the per capita gross national income of Bangladesh (United States dollars, US$ 470).
Aquaphor and SSO were both highly cost-effective relative to control, reducing neonatal mortality by 26% and 32%, respectively. SSO cost US$ 61 per death averted and US$ 2.15 per YLL averted (I$ 6.39, international dollars, per YLL averted). Aquaphor cost US$ 162 per death averted and US$ 5.74 per YLL averted (I$ 17.09 per YLL averted). Results were robust to sensitivity analysis. Aquaphor was cost-effective relative to SSO with 77% certainty: it cost an incremental US$ 26 more per patient treated, but averted 1.25 YLLs (US$ 20.74 per YLL averted).
Topical therapy with SSO or Aquaphor was highly cost-effective in reducing deaths from infection among the preterm neonates studied. The choice of emollient should be made taking into account budgetary limitations and ease of supply. Further research is warranted on additional locally available emollients, use of emollients in community-based settings and generalizability to other geographic regions.
在孟加拉国的一家三级医院评估局部保湿剂、葵花籽油(SSO)和合成 Aquaphor 与不治疗相比预防住院早产儿(<33 周)死亡率的成本效益。
使用标准蒙特卡罗模拟评估来自随机对照疗效试验的证据。项目成本是从对活动的回顾性审查中获得的。患者成本是从患者记录中收集的。健康结果计算为避免的死亡人数和避免的生命年损失(YLL)。如果结果低于基于孟加拉国人均国民总收入(孟加拉国美元,470 美元)的上限比率,则认为是具有成本效益的。
与对照组相比,Aquaphor 和 SSO 均具有高度成本效益,分别降低新生儿死亡率 26%和 32%。SSO 每避免 1 例死亡的成本为 61 美元,每避免 1 个 YLL 的成本为 2.15 美元(每 YLL 避免 6.39 美元,国际美元)。Aquaphor 每避免 1 例死亡的成本为 162 美元,每避免 1 个 YLL 的成本为 5.74 美元(每 YLL 避免 17.09 美元)。结果对敏感性分析具有稳健性。Aquaphor 相对于 SSO 具有 77%的成本效益确定性:每个接受治疗的患者多花费 26 美元,但避免了 1.25 个 YLL(每 YLL 避免 20.74 美元)。
局部使用 SSO 或 Aquaphor 治疗在降低研究早产儿感染性死亡方面具有很高的成本效益。应该根据预算限制和供应的便利性来选择保湿剂。需要进一步研究其他当地可用的保湿剂、在社区环境中使用保湿剂以及在其他地理区域的推广。